Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01006252 · ClinicalTrials.gov registry record · Phase 3
A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 336
- Enrollment target
NCT01006252: Clinical Trial Phase 3 study, sponsored by Eli Lilly and Company.
NCT01006252 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 336 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01006252, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 336 participants
- Enrollment target
Study Summary
The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.
Primary Outcome
OS is duration from enrollment to death; OS censored for participants who were alive at last contact.
Interventions
- DRUG Paclitaxel
- DRUG Tasisulam-sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Why NCT01006252 stopped before completion
NCT01006252 is an interventional study that assigns participants to a tested intervention. The registered 336 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT01006252 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01006252 about?
NCT01006252 is a clinical study titled "A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma". The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.
What is the current status of trial NCT01006252?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 336 participants. The study started on 2009-12. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01006252?
The interventions under investigation include: Paclitaxel (DRUG), Tasisulam-sodium (DRUG).
Who is sponsoring clinical trial NCT01006252?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01006252's enrollment target sits among peer trials
336 1060th of 2000 higher than 940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- NCT03977207 · 336 participants · NA
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients
- NCT04665206 · 336 participants · Phase 1
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- NCT05124457 · 336 participants · Phase 2
DETERMINE: Detemir vs NPH
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia